Safety of selamectin in cats.
The safety of the avermectin, selamectin, was evaluated for topical use on the skin of cats of age six weeks and above, including reproducing cats and cats infected with adult heartworms. All studies used healthy cats. Acute safety was evaluated in domestic cross-bred cats. Margin of safety was evaluated in domestic-shorthaired cats, starting at six weeks of age. Reproductive, heartworm-infected, and oral safety studies were conducted in adult, domestic-shorthaired cats. Studies were designed to measure the safety of selamectin at the recommended dosage range of 6-12mgkg(-1) of body weight. Assessments included clinical, biochemical, pathologic, and reproductive indices. Selected variables in the margin of safety study and the reproductive studies were subjected to statistical analyses by using a mixed linear model. Cats received large doses of selamectin at the beginning of the margin of safety study when they were six weeks of age and at their lowest body weight, yet displayed no clinical or pathologic evidence of toxicosis. Similarly, selamectin had no adverse effect on reproduction in adult male and female cats. There were no adverse effects in heartworm-infected cats. Oral administration of the topical formulation, which might occur accidentally, caused mild, intermittent, self-limiting salivation and vomiting. Selamectin is a broad-spectrum avermectin endectocide that is safe for use in cats starting at six weeks of age, including heartworm-infected cats and cats of reproducing age, when administered topically to the skin monthly at the recommended dosage to deliver at least 6mgkg(-1).
Animal Health Clinical Affairs, Central Research Division, Pfizer Inc., Groton, CT 06340, USA. matthew_j_krautmann@groton.pfizer.com
M J
MJ
Krautmann
M J
MJ
Novotny
K
K
De Keulenaer
C S
CS
Godin
E I
EI
Evans
J W
JW
McCall
C
C
Wang
T G
TG
Rowan
A D
AD
Jernigan
D000284:Administration, Oral; D000818:Animals; D000871:Anthelmintics / Q000009:adverse effects / Q000627:therapeutic use*; D000977:Antiparasitic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002415:Cats; D004184:Dirofilariasis / Q000188:drug therapy*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004478:Ectoparasitic Infestations / Q000188:drug therapy / Q000662:veterinary*; D005260:Female; D005333:Fetus / Q000187:drug effects; D007559:Ivermectin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D011247:Pregnancy; D012098:Reproduction / Q000187:drug effects
D000871:Anthelmintics; D000977:Antiparasitic Agents; D007559:Ivermectin; C019264:avermectin; C414354:selamectin